Title: Chemsex behaviours among men who have sex with men: A systematic review of the literature

Steven Maxwell, Maryam Shahmanesh, Mitzy Gafos

Authors names and affiliations:
Steven Maxwell (corresponding author)
Senior Teaching Fellow
King’s College London
James Clerk Maxwell Building
57 Waterloo Road
London
SE1 9NN
steven.maxwell@kcl.ac.uk

Maryam Shahmanesh
Senior Clinical Lecturer
Institute for Global Health
University College London
Capper Street
London
WC1E 6JB
m.shahmanesh@ucl.ac.uk

Mitzy Gafos
Associate Professor
STRIVE Co-Research Director
Department of Global Health and Development
London School of Hygiene and Tropical Medicine
15-17 Tavistock Place, London WC1H 9SN
Mitzy.Gafos@lshtm.ac.uk
Abstract

**Background:** ‘Chemsex’ is the use of drugs before or during planned sexual events to facilitate, enhance, prolong and sustain the experience. Drugs associated with chemsex are methamphetamine, GHB/GBL, mephedrone, cocaine and ketamine. This review synthesizes published research on the antecedents, behaviours and consequences associated with chemsex behaviours among men who have sex with men (MSM).

**Methods:** Papers from high income countries which were published between January 2000 and September 2018 reporting the use of chemsex drugs before or during sex were identified through Medline, Web of Science, CINAHL and Central. Results were synthesised using a narrative approach and conceptualised using a behavioural analysis framework.

**Results:** The search identified 2492 publications, of which 38 were included in the final synthesis. There were wide variations in chemsex prevalence estimates due to the heterogeneous sampling in the studies. Chemsex participants have expectations that the drugs will positively affect their sexual encounters and HIV positive MSM are more likely to engage in the behaviour than HIV negative MSM. There were wide ranging prevalence estimates on injecting drugs for sexual purposes and the sharing of injecting equipment with some evidence of unsafe injecting practices. Participants were more likely to engage in condomless anal intercourse than men who do not engage in chemsex. This may increase the risk of transmission for HIV and other sexually transmitted infections.

**Conclusion:** A minority of MSM appear to engage in chemsex behaviours but they are at risk of this negatively impacting on their health and well-being. Further research is required to examine high risk chemsex behaviours, impact of chemsex on psycho-social well-being and if chemsex influences uptake of PrEP, PEP and sexual health screening.

**Keywords**

Chemsex
Men who have sex with men
Sexualised drug use
Sexual risk behaviour
Slamming
Introduction

Men who have sex with men (MSM) can have significant and multi-faceted relationships with drugs and alcohol. Public Health England ([PHE], 2014) identify an alcohol dependence rate among MSM that is double that of the non-MSM male population. The Office for National Statistics ([ONS], 2014) report gay and bisexual men to be three times more likely to use illicit substances than their heterosexual counterparts. One quarter of a sample of MSM drawn from twenty sexual health clinics in England report using three or more recreational drugs in the previous three months (Sewell et al, 2017). However, sexual health clinic samples are likely to provide over-estimates for substance use behaviours and differences would also be expected between metropolitan samples of MSM and country-wide estimates. However, poly drug use is a recognised concern among MSM particularly those who use drugs before or during sex.

Sexualised drug use (SDU) refers to the use of any illicit drug just before or during sex and a subset term of SDU is referred to as ‘chemsex’ (Edmundson et al, 2018). Chemsex behaviours are described as the use of specific drugs before or during planned sex to facilitate, initiate, prolong, sustain and intensify the encounter (PHE, 2015; Bourne et al, 2015). Certain drugs have been associated with chemsex behaviours including mephedrone, methamphetamine, and GHB/GBL (Gamma hydroxybutyrate/Gamma butyrolactone) (PHE, 2015). In a London based study cocaine and ketamine were also linked to the behaviours (Bourne et al, 2014). A high-risk behaviour associated with chemsex involves the injecting of a drug for sexual purposes (PHE, 2015). The concept of ‘chemsex’ is socially constructed and as such is subject to the preferences of participants and the popularity and availability of specific drugs. Furthermore, these features are likely to vary across countries and among sub-cultures within countries, as well as across time.

There have been growing concerns about the interconnected nature of high risk drug/sexual behaviours and the increased transmission risk of blood borne viruses (BBV) and sexually transmitted infections (STIs) (PHE, 2015). In the United Kingdom (UK) MSM account for more than half of all new human immunodeficiency virus (HIV) infections which demonstrates that they are disproportionately affected by the disease in comparison to the general population (PHE, 2016). The advent of HIV antiretroviral therapy and pre-exposure prophylaxis (PrEP) provide protection by reducing the risk of onward transmission and acquisition. However, the effectiveness of these medicines is reliant on patient adherence and there is limited evidence on the impact of chemsex behaviours on medication adherence. In addition to the biological risk, there is increasing concerns that chemsex may be associated with psychosocial risks. Tomkins et al (2018) identified that there is growing evidence which indicates that chemsex is potentially associated with the mental ill health of MSM who engage in the activity. This highlights that there are potentially multiple biopsychosocial risk factors for MSM that engage in chemsex behaviours.

Chemsex has attracted international clinical and research attention from which there is an emerging body of knowledge on different aspects of the behaviour. For example, its prevalence (Heiligenberg et al, 2012), sociodemographic characteristics associated with the behaviour (Obera et al, 2009), patterns of drug use and sexual behaviours (Benotsch et al. 2012), biopsychosocial impact of the behaviour (Hegazi et al, 2017),
and associations with HIV (Bourne et al, 2015). In early 2018 two published literature reviews (Edmundson et al, 2018; Tomkins et al, 2018) examined some aspects of chemsex but had a wider focus on MSM sexualised drug use. To date, we are not aware of a literature review that has specifically examined the research related to chemsex drug use before or during sex. As chemsex participants health is potentially at high-risk there is a need to systematically interrogate the literature on chemsex drug use within a sexualised setting. This review will comprehensively analysis the behaviours involved in chemsex activities, including the risks they present to participants. The review will help inform the development of evidence-based risk reduction strategy and provide recommendations on the need for further research.

Methods

The research team anticipated that different methods and means of measurement would characterise the literature in the emerging evidence base on chemsex behaviours. This review was conducted as a narrative review, guided by a conceptual framework and drawing on systematic methodology as far as possible to promote transparency and replicability with results reported according to PRISMA guidelines (Liberati et al., 2009).

Chemsex behaviours are activities for which the antecedent-behaviour-consequence (ABC) framework provides a useful way to map potential variables of interest. Table 1 contains a provisional ABC analysis of chemsex drawn from the literature and from research team discussions. It provides a framework to organise review findings and to specify the review’s objectives:

1. To establish prevalence estimates for chemsex behaviour among MSM;
2. To document chemsex behaviour in terms of drugs used, high risk drug use behaviour, sexual risk behaviour and characteristics of the drug use setting;
3. To gauge whether sex sessions that include drugs differ from those that do not in terms of the behaviours and associated risks;
4. To identify factors associated with chemsex behaviour, including HIV status, individual’s socio-demographics and expectations of participation;
5. To identify any bio-medical risk reduction interventions used by chemsex participants and whether their use is compromised when drugs are combined with sex;
6. To identify the biopsychosocial impact of chemsex behaviour on participants, including risk of STI/BBV infection and the psychosocial impact.

There are challenges to identifying and reaching representative populations of MSM who engage in chemsex behaviours. Added to this are the challenges of classifying and measuring a varied, uncommon set of human behaviours. The sampling frames of the studies included in this review will by extension be heterogeneous and not representative, making accurate population estimates unrealistic. For example, where studies have recruited samples from sexual health or drug treatment services, prevalence is likely to be over-estimated. The context for each study and its potential effects on prevalence are addressed when estimates are presented in the review.

Table 1: ABC analysis of chemsex behaviour between MSM
### Eligibility criteria

This review includes studies of chemsex behaviours that involve drug use before or during sex with any one of the following drugs: methamphetamine, mephedrone, GHB/GBL, cocaine and ketamine. To be able to consider HIV risk reduction strategies during chemsex behaviours, alongside other potential biopsychosocial harms and protective mechanisms, studies were included that sampled HIV negative MSM or those whose HIV status was unknown. Studies that exclusively sampled HIV positive MSM were excluded. The review includes studies of primary research from high income countries, as defined by the World Bank, which were published in peer review journals in the English language between 1st of January 2000 and 1st of September 2018.

### Information sources and search

Four databases were used for the search; Medline, CINAHL, Web of Science and CENTRAL. The databases were selected to reflect medical, nursing, allied health professionals, sociological and clinical trial journals. Table 2 presents the MESH terms and key words that were used for the search. One reviewer conducted the search using a predefined protocol which was developed in combination with another two senior researchers. The search was conducted initially in December 2017 and was updated in September 2018.

**Table 2:** PIO search terms

<table>
<thead>
<tr>
<th>Population</th>
<th>Intervention</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men who have sex with men (MSM)</td>
<td>Chemsex</td>
<td>Sexually transmitted infection(s)</td>
</tr>
<tr>
<td>Homosexual me(a)n</td>
<td>Party and play</td>
<td>Sexually transmitted disease(s)</td>
</tr>
<tr>
<td>Gay me(a)n</td>
<td>Sexualised drug use</td>
<td>HIV</td>
</tr>
<tr>
<td>Gay male(s)</td>
<td>Slamming</td>
<td>Hepatitis C</td>
</tr>
<tr>
<td></td>
<td>Substance use disorder(s)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Illicit drug use</td>
<td></td>
</tr>
</tbody>
</table>

### Study selection

Data retrieved through the search were extracted onto Endnote x8 (Thomson Reuters, New York, USA). At the abstract stage an independent reviewer examined a random
sample of abstracts (10% of those excluded and 20% of those included) to ensure the robust application of the inclusion and exclusion criteria. A third researcher was available to resolve any differences through discussion.

**Risk of bias assessment in individual studies**

A risk of bias assessment was performed for each study by one reviewer. The National Heart, Lung and Blood Institute (NHLBI) tool was used to assess the clarity and rigour of the outcomes/measures, sample recruitment, data collection and statistical analysis process of quantitative studies that were cohort/cross sectional in design. Critical Appraisal Skills Programme (CASP) checklists were used to assess the clarity and rigour of the recruitment strategy, data collection/analysis methodology, ethical considerations and presentation of findings of qualitative studies. The primary strengths and limitations of the methodologies of the papers are summarised in the findings section.

**Data collection process and data items collected**

Data from the studies included in the analysis were extracted by one reviewer onto a structured data extraction template. The following variables were extracted: authors, title, year published, study aim, data collection period, study design, study location, setting, data collection/analysis methodology and variables of interest as defined in table 1.

**Data analysis**

The narrative approach to synthesis uses words and text to ‘tell the story’ of the findings. Popay et al’s (2006) four stage framework and techniques are used to increase the transparency and trustworthiness of the narrative synthesis. The literature in this review is used to understand a behavioural event and Table 1 provides an initial theoretical model of that behavioural event. The ABC framework is utilised to organise and compare evidence and was subject to alterations and refinements as synthesis progressed.

**Results**

**Study selection**

The number of studies identified, reviewed and selected with reasons for exclusion are summarised in Fig 1. The initial total number of articles captured from the search was 3438, which after removing duplicates was 2653. On reviewing article titles there were 2362 excluded which left 291 articles for abstract screening. Eighty articles met final inclusion and at full reading there were forty-two excluded; one was not English language, five did not fully published primary research data and 36 were not explicitly on chemsex drug use which is before or during a sexual encounter. Ten articles (5 UK: two data sets, 2 Canadian: one data set, 3 Australia: one data set) were based on data from four samples but had been used for different study objectives. A final total of 38 articles were included the review.
Study selection and characteristics

Table 3 provides a summary on the aim, population, country, sample size, year of data collection, study design and ABC key findings of the 38 articles included in the review. The findings section will be presented in the ABC headings but structured as, 1: behavior, 2: antecedents, 3: consequences. Fig.2 provides a summary of the review’s main findings which is structured using the ABC framework. The sample size from all the studies ranged from 14 to 6757 participants with data collected from 2001 to 2017. The majority of the studies are from the North Americas (13- USA, 2- Canada) or Europe (10- UK, 1- Republic of Ireland (ROI), 1- European wide, 1- UK and ROI, excluding England, 1- Germany, 3- Netherlands) and only six are from outside these areas, which includes five from Australia and one from Israel. The majority of the studies are quantitative cross-sectional studies (26) or qualitative studies (9) with two retrospective case note reviews and one observational cohort study. Thirty-one studies reported HIV prevalence rates ranging from 1% to 80%. Only four studies exclusively focused on HIV negative MSM and three studies did not report HIV prevalence rates in their sample. The diverse nature of the samples may explain the
wide variations in HIV prevalence. Some studies specifically recruited MSM engaged in chemsex whilst others tried to recruit representative samples of MSM. There was also variation in chemsex prevalence estimates, which may be accounted for by the different settings in which studies were conducted. For example, recruitment using multiple digital media platforms and participants recruited from specific clinical services.

**Fig 2. ABC Summary of Findings**

* the overall prevalence %’s for chemsex engagement incorporates higher level estimates of samples from sexual health clinics
** the overall prevalence %’s for injecting incorporates higher level estimates of samples from drug services

**Risk of bias assessment in individual studies**

The NHLBI tool grades all the quantitative cross-sectional and case note review studies as ‘fair’ in terms of their quality. All these studies were rated at this level due to limitations in this design which only provided a ‘snapshot’ at one point in time. Most of these studies did not provide a sample size justification, only measured the exposures once and it is unclear if the researchers were blinded to the status of the sample. The primary strengths in most of these studies were the clear objectives, a defined sample being recruited, defined exposures/outcomes and appropriate methodology for data analysis. The majority of the qualitative studies provided a clear recruitment strategy, justified the data collection methods, secured ethics approval, described a rigorous analysis methodology and provided the findings in a clearly structured format. Although the studies briefly discussed key ethics considerations, most of them did not critically examine the role between the researcher or sample. There was limited discussion of the wider ethics issues raised in or from the study.

**Prevalence and type of non-injecting drugs**

Ten articles examined the prevalence of chemsex drugs within general MSM samples and most of the articles are from the USA and Western Europe (Koblin et al, 2007; Mor et al, 2008; Prestage et al, 2009; Heiligenberg et al, 2012; McCarty-Caplan et al,
The majority of the studies each examined numerous sex related drugs but two from the USA specifically focused on two stimulants (*methamphetamine* and *cocaine*) (Koblin et al, 2007, Benotsch et al, 2012).

Eight studies provided an overall prevalence for chemsex related behaviour which incorporates various drugs, this ranges from 3%-29% (McCarty-Caplan et al, 2014; Hegazi et al, 2017; Rosinska et al, 2018; Druckler et al, 2018; Pakianathan et al, 2018; Glynn et al, 2018; Frankis et al, 2018; Hammoud et al, 2018b). Prevalence estimates which range from 17%-27% were all of MSM attending sexual health clinics and the 29% estimate is from an online survey which only used one MSM geo-social dating app to recruit the sample (Glynn et al, 2018; Hegazi et al, 2017; Druckler et al, 2018; Pakianathan et al, 2018; Hammoud et al, 2018b). The four other studies provided estimates between 3%-13% but they used a wider selection of online platforms to recruit MSM samples (McCarty-Caplan et al, 2014; Frankis et al, 2018; Rosinska et al, 2018, Hammoud et al, 2018b). Rosinska et al (2018) conducted an online survey of MSM across thirteen different European cities which provided a prevalence range of between 0%-14%. Chemsex prevalence varies widely across different countries but the evidence is limited with most of samples being recruited from cities or sexual health clinics.

Six studies provided use rates for the three drugs primarily connected to chemsex (*methamphetamine*, *mephedrone*, *GHB/GBL*) (Frankis et al, 2018; Druckler et al, 2018; Pakianathan et al, 2018; Glynn et al, 2018; Hegazi et al, 2017; Melendez-Torres, 2016). All studies were from Western Europe and the majority recruited MSM samples from sexual health clinics. Mephedrone was the most commonly used in two UK studies and the least used in three other three studies from the UK, ROI and the Netherlands (Pakianathan et al. 2018; Frankis, 2018; Druckler et al, 2018; Hegazi et al 2018; Melendez-Torres et al, 2016, Glynn et al, 2018). Seven studies specifically examined rates of GHB/GBL use. In five studies GHB/GBL was the most commonly used chemsex drug but in two other studies it was the second mostly commonly used (Hegazi et al, 2017; Melendez-Torres et al, 2016; Heiligenberg et al, 2012, Frankis et al, 2018, Druckler et al, 2018; Pakianathan et al. 2018; Glynn et al, 2018). A study from Australia which only examined the use of GHB/GBL reported that 5% of the MSM sample had used the drug in the previous 6 months (Hammoud et al, 2018a). With the exception of this study, all the other studies that examined GHB/GBL were from Western Europe. The five studies which suggested that GHB/GBL was the most commonly used drug originate from the Netherlands, UK and Ireland and most of the samples were recruited from sexual health clinics.

Eight studies examined the use of methamphetamines, in which five provided prevalence estimates ranging from 3%-22%. From these studies the three USA (2007-12) stimulant focused articles reported a prevalence range of 9%-22% (Koblin et al, 2007; Mor et al, 2008; Ober et al, 2009; Benotsch et al, 2012; Heiligenberg et al, 2012). The highest rate of 22% was from the study by Ober et al (2009), which consists of MSM with a low income and high rates of previous homelessness. With the exemption of this study, the methamphetamine prevalence range was from 3%-10%. McCarty-Caplan (2014) in the Chicago study reported an overall chemsex related behaviour prevalence rate of 10% which is comparable to the prevalence results of the two USA methamphetamine studies of 9%-10%. (Koblin et al, 2007; Benotsch et
al, 2012). Six of eight studies that examined the use of various substances all identified that methamphetamine was among the highest three most commonly used chemsex drugs (Mor et al, 2008; Hegazi et al, 2017; Melendez-Torres et al, 2016; Heiligenberg et al, 2012; Frankis et al, 2018, Druckler et al, 2018; Pakianathan et al. 2018;).

The use of cocaine was examined in seven studies and ketamine within six studies. Three of the studies related to cocaine provided prevalence estimates ranging from 2%-33% (Mor et al, 2008; Ober et al, 2009; Heiligenberg et al, 2012). The highest rate of 33% was from the Ober et al study and with the exception of this study the cocaine estimates range from 2%-15%. Four of the studies which examined the use of varying chemsex drugs indicated that cocaine was one of the least used drugs (Mor et al, 2008; Hegazi et al, 2017; Melendez-Torres et al, 2016; Pakianathan et al, 2018). Two of the studies related to ketamine reported a prevalence ranging from 1%-4% and four studies ranked ketamine as one of the least used chemsex drugs (Mor et al, 2008; Heiligenberg et al, 2012; Hegazi et al, 2017; Frankis et al, 2018; Pakianathan et al. 2018). Only two studies from the Netherlands and ROI found ketamine was used more frequently than methamphetamine (Heiligenberg et al, 2012; Glynn et al, 2018).

Prevalence and type of injecting drugs

Nine of the studies examined MSM injecting drug use for sexual purposes which provided prevalence estimates ranging from 1%-50% (Gilbart et al, 2015; Hopwood et al, 2015; Bowden-Jones, 2017; Hegazi et al, 2017; Ahmed et al, 2017; Bui et al, 2018; Frankis et al, 2018; Druckler et al, 2018; Glynn et al, 2018). Five studies which examined this in large MSM samples reported a prevalence range of 1%-9% and within three of the studies methamphetamine was the most commonly injected drug (Hopwood et al, 2015, Frankis et al, 2018; Glynn et al, 2018; Druckler et al, 2018; Bui et al, 2018). The remaining four studies targeted specific MSM populations or had small MSM samples which reported a prevalence range of 25%-50%. These studies may have reported higher rates of injecting because two-focused on chemsex users, one was a small sample diagnosed with shigella and another was a small sample from sexual health clinics. Only one of these studies specified drug types, which indicates that most chemsex injectors primarily use methamphetamine (Bowden-Jones, 2017).

Four studies reported a wide variation in the levels of sharing injecting equipment which ranges from 5%-56%, although the three most recent studies reported a range of 5%-12% (Hegazi et al, 2017; Hopwood et al, 2015; Bowden-Jones et al, 2017; Bui et al, 2018). Gilbart et al (2015) highlighted that their study sample had a low level of knowledge related to the risks of BBV transmission. Only one study from Australia identified that the injecting of drugs was associated with multiple partners and group sex (Bui et al, 2018). From the evidence it appears methamphetamine is the most commonly injected drug and there are variations in the extent to which users adopt safe injecting practices. However, there are limitations in determining injecting prevalence and associated risk behaviours due to the heterogeneous nature of the samples in the studies.
Drug Use Setting

Thirteen of the studies examined elements of the environments and related drug use patterns linked to chemsex related behaviors (Ober et al, 2009; Prestage et al, 2009; Grov et al, 2013; Bourne et al, 2015; Rich et al, 2016a; Rich et al, 2016b; Gilbart et al, 2015; Deimel et al, 2016; Melendez-Torres et al, 2016; Ahmed et al, 2017, Melendez-Torres, 2017; Rusow et al, 2017, Bowden-Jones, 2017). Most of these studies involved specific samples of MSM; five focused on varying elements of drug using MSM and three on MSM who engaged in group sex or multi-partner sexual encounters. All the studies indicated that there was a complex two-way interface between MSM using specific drug types to facilitate multi-partner sexual events, within which the venue plays an integral role.

Five studies showed that chemsex related activities primarily occurred in sex on premise venues (SPV) (bath houses/saunas) or private homes (Ober et al, 2009; Bourne et al, 2015; Rusow et al, 2017; Ahmed et al, 2017; Melendez-Torres, 2016;). Two studies highlighted that between 22%-38% of encounters took place in SPVs and 52%-66% within private homes (Melendez-Torres, 2016; Ober et al, 2009). Two UK studies highlighted that with the growth in MSM using geo-social networking platforms, there is potentially a change in chemsex being more likely to occur in private homes (Ahmed et al, 2017; Bourne et al, 2015). Three studies from Western Europe reported that chemsex based sex parties mostly involved multiple casual partners and can last from a few hours to several days (Deimel et al, 2016; Gilbart et al, 2015; Bourne et al, 2015).

Prestage et al (2009) reported that 63% of an MSM group sex attendee sample had consumed illicit drugs at a group sex event in the previous six months. In comparison, a more recent study from a UK club drug clinic highlighted that 75% of the MSM sample had used the primary chemsex related drugs (mephedrone, methamphetamine, GHB/GBL) to facilitate sex (Bowden-Jones et al, 2017). Three studies indicated that consumption of varying stimulants occurred at group sex events, which could include methamphetamine, GHB/GBL, mephedrone, ecstasy, cocaine and ketamine (Grov et al, 2013; Rich et al, 2016a; Prestage et al, 2009). Three studies reported that between 14%-26% of MSM attending sex parties consumed erectile disorder drugs (EDDs) and within two studies EDDs were more likely to be associated with methamphetamine use (Gilbart et al, 2015; Melendez-Torres, 2016; Prestage et al, 2009). Gilbart et al (2015) found MSM chemsex participants were more likely to use EDDs to counteract the physiological effect of methamphetamine.

Sexual behaviour

Seventeen studies identified that there can be an increased risk of condomless anal intercourse (CAI) when chemsex drugs were combined with sex (Koblin et al, 2007; Ober et al, 2009; Prestage et al, 2009; Benotsch et al, 2012; McCarty-Caplan, 2014; Melendez-Torres, 2016; Ottaway et al, 2017; Melendez-Torres et al, 2017; Gilbart et al, 2015; Bourne et al, 2015; Ahmed et al, 2017, Reback et al, 2018; Glynn et al, 2018; Druckler et al, 2018, Hoornenborg et al, 2018; Frankis et al, 2018). Only three studies, with specific and limited samples, provided rates of CAI which are explicitly when chemsex drugs are combined with sex, which ranges from 30%-38% (Ober et al, 2009; Bourne et al, 2015; Melendez-Torres et al, 2016). Five UK studies identified that when
the sexual encounter involved chemsex drugs there was a higher likelihood of men performing esoteric sex acts (for example: fisting) (Hegazi et al, 2017; Ahmed et al, 2017; Gilbart et al, 2015; Frankis et al, 2018; Pakianathan et al. 2018). Two of these studies had high rates of HIV positive men in the sample and one study had a small sample of men diagnosed with shigella.

Six of the studies examined the associations between specific drug types and the likelihood of engaging in high risk sexual activity. All of these studies found that methamphetamine use with sex was associated with CAI but only one study found this was distinctly with HIV negative sex partners (Koblin et al, 2007; Ober et al, 2009; Prestage et al, 2009; Benotsch et al, 2012; Melendez-Torres et al, 2016; Reback et al, 2018). One of these studies found there was an interconnection between the use of methamphetamine and EDDs with sex, which increased levels of CAI (Melendez-Torres et al, 2016). Evidence for other specific drugs was limited but this may be due to studies focusing on methamphetamine use.

Bio-medical risk reduction interventions

Ten studies examined elements of STI/BBV testing, post-exposure prophylaxis (PEP), PrEP and injecting equipment provision (IEP) services (Prestage et al, 2009; Gilbart et al, 2015; Hopwood et al, 2015; Hegazi et al, 2017; Pakianathan et al. 2018, Frankis et al 2018; Druckler et al, 2018; Hammoud et al, 2018a; Hammoud et al, 2018b; Closson et al, 2018). One Australian study highlighted that 89% of the sample had ever had an HIV test and a more recent UK study identified that 94% of the sample had ever attended sexual health services (Prestage et al, 2009; Gilbart et al, 2015). However, the UK study is unlikely to be representative as 63% of the sample were HIV positive. Hopwood et al (2015) identified that in the previous 12 months 72% of the HIV negative men had tested for HIV and 77% of the HCV negative men had tested for HCV. A recent study from Western Europe identified that the likelihood of engaging in chemsex is greater if MSM have had an HIV test in the previous 3 months (Frankis et al, 2018).

Two studies identified that chemsex participants were more likely to access PEP than non-chemsex participants. (Hegazi et al, 2017; Pakianathan et al. 2018). An Australian study reported that 80% of the PrEP users had not engaged in chemsex in the previous 6 months, although this was a relatively small sample and 16% did not answer the chemsex question (Hammoud et al, 2018b). However, a Netherlands study highlighted that MSM who engaged in chemsex were more likely to be on PrEP than MSM who did not participate in the activity (Druckler et al, 2018). A study which explored MSM chemsex participants’ views of PrEP highlighted that more regular drug users would prefer daily dosing and less frequent drug users would opt for episodic dosing (Closson et al, 2018). Gilbart et al (2015) identified that most MSM who injected chemsex drugs were generally unaware of injecting equipment service provision and safer injecting practices. However, this study had a small sample diagnosed with shigella. Based on this evidence it is difficult to conclude how MSM chemsex participants utilise bio-medical interventions.
Socio-demographics of participants

Thirteen studies examined elements of key socio-demographics of MSM samples that used chemsex related drugs before or during sex and the majority of the studies are from the USA and UK. Eight studies provided a mean or median age for chemsex participants, ranging from 32 to 42 (Green & Halkitis, 2006; Weatherburn et al, 2016; Hegazi et al, 2017; Benotsch et al, 2012; Reback et al, 2018; Druckler et al, 2018; Rosinska et al, 2018; Closson et al, 2018) and one study into chemsex injectors reported a median age of 42 (Hopwood et al, 2015). Frankis et al (2018) identified that MSM between the ages of 36-45 were more likely to engage in chemsex. In the six studies that reported sexual identity, the majority of the sample identify as gay (Green and Halkitis, 2006; Benotsch et al, 2012; Hopwood et al, 2015; Weatherburn et al, 2016; Reback et al, 2018; Closson et al, 2018) and in six of the seven studies that reported ethnicity, most of the sample identified as white (Green and Halkitis, 2006; Benotsch et al, 2012; Weatherburn et al, 2016; McCarty-Caplan, 2014; Druckler et al 2018; Closson et al, 2018).

Rusow et al (2017) found in a USA study that MSM who combined methamphetamine with sex were significantly more likely to be white and identify as being gay. In another USA study, methamphetamine had higher rates of use in white and Hispanic populations, but they were less likely to use cocaine when compared to black MSM (Ober et al, 2009). In comparison, a USA study reported that white MSM used less cocaine with sex compared to ethnic groups (Reback, 2018), but this study may be limited by the small number of white MSM in the sample. From this limited evidence it is not clear if ethnicity is a determining factor for engaging in chemsex. Two studies identified that chemsex participants spend most of their time with other gay men but does not necessarily mean that most of their social network consists of friends who were gay men (Kelly et al, 2012; Hopwood et al, 2015). It appears from the overall evidence that chemsex participants were more likely to be a gay man and participation peaks between the mid-thirties to early forties but is evident at all ages.

Role of HIV status

Eleven studies identified that HIV positive MSM were more likely to use chemsex drugs with sex, when compared to MSM of non-HIV positive status (Ober et al, 2009; McCarty-Caplan, 2014; Rich et al, 2016b; Gilbart et al, 2015; Hegazi et al, 2017; Bowden-Jones et al, 2017; Rusow et al, 2017; Frankis et al, 2018; Rosinska et al, 2018; Hammoud et al, 2018a; Pakianathan et al. 2018). Only one study provided an analysis on the role of HIV status in injecting drug use, which found HIV positive status was associated with recent injecting and sharing of injecting equipment (Bowden-Jones et al, 2017). In comparison, a study on injecting drug use reported recent injectors were significantly more likely to be HIV positive when compared to other study participants (Bui et al, 2018). Due to the limited evidence it is not possible to substantively conclude what role HIV plays in the injection of drugs for sexual purposes.

Four studies reported that within chemsex related behaviour HIV positive MSM were more likely to sero-sort and engage in CAI with HIV positive partners (Gilbart et al, 2015; Bourne et al, 2015; Melendez-Torres et al, 2016; Rich et al, 2016a). One study found that there was less incidence of CAI at sexual encounters when partner HIV
status was sero-discordant or unknown (Melendez-Torres et al, 2017). The evidence indicates HIV status is potentially an important factor in determining if men that engage in chemsex use condoms.

**Expectations of the event**

Twelve articles indicated that MSM who engage in chemsex related behaviors may have perceptions and expectations that the desired physiological effects of a drug will alter a sexual event (Kurtz, 2005; Green and Halkitis, 2006; Kubicek et al, 2007; Jerome et al, 2009; Benotsch et al, 2012; Bourne et al, 2015; Deimel et al, 2016; Weatherburn et al, 2016; Ahmed et al, 2017; Prestage et al, 2009; Bui et al, 2018; Hammoud et al, 2018a). These studies were primarily qualitative and from the UK and USA. There were variable and multi-faceted effects when chemsex drugs were combined with sex, but these can be categorised into primary domains. The findings from the articles can be themed into physical, mental, emotional and social domains. Fig 3. provides a summary of drug effects and the potential desired outcomes that alter the sexual event.

Most of the studies found that a key effect is the ability to increase stamina and arousal levels, so an individual can engage in sex for sustained periods and facilitate easier receptive anal intercourse/sex acts (Kurtz, 2005; Green and Halkitis, 2006; Kubicek et al, 2006; Jerome et al, 2009; Bourne et al, 2015; Deimel et al, 2016; Ahmed et al, 2017; Weatherburn et al, 2016; Prestage et al, 2009; Bui et al, 2018; Hammoud et al, 2018a). Some of the studies reported that the reduction in cognitive inhibition allowed the men to overcome under confidence and enhanced their ability to engage more meaningfully with sex partners (Green and Halkitis, 2006; Jerome et al, 2009; Weatherburn et al, 2016). The lowering of inhibitions may be important in establishing more immediate and sustained interaction with sex partners, providing a more meaningful shared sexual experience. Some of the studies identified that the increase in awareness and intensity of feeling was important for men to enhance their emotional connection with partners during sex (Green and Halkitis, 2006; Jerome et al, 2009; Weatherburn et al, 2016). There are interactions between all these domains with an overarching theme being to maximise the intensity of a sexual event.

**Fig 3.** Expected drug effects on the sexual event

<table>
<thead>
<tr>
<th>Drug Effect</th>
<th>Desired enhancements</th>
<th>Sexual Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>decrease inhibitions</td>
<td>facilitate receptive anal intercourse/esoteric acts and maximise sexual performance/sensation</td>
<td></td>
</tr>
<tr>
<td>alter cognitive pathways</td>
<td>alter perception which intensifies the 'in the moment' sexual acts/experience</td>
<td></td>
</tr>
<tr>
<td>muscle relaxant effect</td>
<td>increased confidence and enhance the ability to engage with partners</td>
<td></td>
</tr>
<tr>
<td>increase energy</td>
<td>intensity self-emotion awareness and shared experience with partners</td>
<td></td>
</tr>
</tbody>
</table>
Biological Impact

As indicated earlier, HIV positive men are potentially more likely to engage in high risk chemsex related behaviours. However, it is important to recognise that a significant number of HIV negative MSM may engage in chemsex and be at risk of HIV. Seven studies that had a majority of drug users in their samples, reported an assumed HIV negative prevalence range of 20% to 59% (Kurtz et al, 2005, Green and Halkitis, 2006; Bourne et al, 2015; Hopwood et al, 2015; Bowden Jones et al, 2017; Deimel et al, 2016; Reback et al, 2018). From the earlier evidence, it is apparent that when drugs are combined with sex that there is an increased risk of men engaging in CAI. An important variable for rates of CAI is the effect of drugs. A few studies identified that drugs effect decision making during sex, which can influence a participant’s choice to engage in high risk sexual practices (Bourne et al, 2105; Gilbart et al, 2015; Ahmed et al, 2017; Deimel et al, 2016). These interconnected factors demonstrate that HIV negative MSM who engage in chemsex related behaviours are potentially at increased risk of disease transmission.

Four studies examined levels of HCV in chemsex related behaviour which identified a prevalence range of 6%-30% and two of these studies report an HIV/HCV co-infection prevalence range of 9%-21% (Hopwood et al, 2015; Bowden-Jones, 2017; Deimel et al, 2016; Bui et al, 2018). The highest rate of 30% was from a study with a small sample size of which approximately 80% were HIV positive. Three of the studies with the highest prevalence rates had samples which primarily consisted of men who injected drugs. Bui et al (2018) identified that recent injectors were more likely to be HCV positive compared to non-recent injectors. There was limited evidence to indicate HCV infection rates among MSM who inject chemsex drugs.

All seven studies that examined components of STIs identified that MSM who engage in chemsex related behaviours have had issues with previous infections (Ottaway et al, 2017; Hegazi et al, 2017; Gilbart et al, 2015; Kurtz, 2005, Druckler et al, 2018; Rosinska et al, 2018; Glynn et al, 2018). One of the studies identified that MSM diagnosed with STIs were more likely to engage in chemsex (Ottaway et al, 2017). In comparison, four studies identified that chemsex participation was associated with the diagnosis or treatment of an STI (Hegazi et al, 2017, Rosinska et al, 2018; Druckler, 2018; Glynn et al, 2018). Ottaway et al (2017) identified that those diagnosed with an STI were more likely to engage in chemsex, were more likely to be HIV positive and have higher rates of CAI. The studies indicated that MSM who engage in chemsex are potentially at a high risk of STI transmission.

Psycho-social impact

Six studies examined aspects on the perceived and actual psychological and social consequences of chemsex related behaviours. A recent study highlighted that 25% of the MSM sample reported that chemsex had a negative effect on their lives (Glynn et al, 2018). Two USA studies highlighted that there is a perception that methamphetamine will have negative consequence on social networks, with the loss of friends & partners (Kurtz, 2005; Kubicek et al, 2007). A USA study highlighted that methamphetamine users reported that sustained use of the drug reduced their ability to fulfil daily functioning (Closson et al, 2018). In comparison, an Australian study identified that the higher the use of GHB reported by the sample, the greater the impact
on the drug user’s social networks (Hammoud et al, 2018a). Two studies identified that chemsex drug use can have an impact upon employment, within one study some men had lost their jobs and in the other study 14% of the men had taken time off work (Kurtz, 2005; Hegazi et al, 2017). One UK study identified that 15% of the sample reported chemsex participation had a negative impact on their mental health and a USA study identified some methamphetamine users experience issues with paranoia (Hegazi et al, 2017; Kurtz, 2005). In comparison, another study reported that poly drug users were more likely to experience psychological distress when compared to sexualised drug users, but this did not attain statistical significance (McCarty-Caplan, 2014). A study on GHB did not find that the drug use was associated with depression or anxiety (Hammoud et al 2018a). There is limited evidence that fully explores the psycho-social impact, although some of the men in the studies had experienced negative consequences directly due to chemsex related behaviours.

Discussion

To our knowledge, this is the first systematic review on chemsex behaviour to exclusively incorporate and examine research on chemsex drug use before or during sex. Two literature reviews (Edmundson et al, 2018: UK research; Tomkins et al, 2018: research from every country) have examined the wider issue of sexualised drug usage among MSM; but did not provide an in-depth analysis of the behaviours involved in the sexualised setting of chemsex drug use. In early 2018 two special journal editions on chemsex were published but the two previous literature reviews did not fully incorporate this research. As such, this is the first comprehensive up to date review of chemsex behaviour which examines participants socio-demographics, expectations of the event, prevalence estimates, high risk behaviours and the biopsychosocial consequences.

This review used the ABC framework as a model to structure the results and conceptualise the behavioural processes involved in chemsex. The key advantage of this approach was the ability to process a complex array of research into an understandable three stage behavioural event. Expectations of the event are a fundamental antecedent that influences MSM who engage in chemsex. MSM that engage in chemsex behaviour expect that drugs may trigger multiple effects on the body that will facilitate, enhance, prolong and sustain a sexual event. Participants may seek a drug’s desirable effects, but the disinhibiting effects may increase the level of risk taking behaviour which subsequently may produce undesirable consequences. HIV is a key influencer through the whole ABC process as HV status can influence the likelihood of engagement in chemsex, effect the event behaviour and HIV transmission can be a potential consequence.

In the wider literature there are large variations in the prevalence estimates for chemsex. The review published by Tomkins et al (2018) identified a prevalence range from 4%-94%, but it incorporates research that does not fit within the PHE definition of chemsex. Edmundson et al (2018) identified that chemsex drugs were also used outside of sexual events and the inter-changeable use of sexualised drug usage and chemsex can cause ambiguity in estimating prevalence levels. Edmundson et al (2018) identified one study with an overall prevalence of 17% and the review identified a range of 3%-29%. However, the majority of prevalence estimates in this review above 15% are based on samples from sexual health clinics. The overall research
indicates that the prevalence of chemsex varies in different countries but also varies within different regions/cities within one country.

It is evident from the findings that there are varying types of drugs used in chemsex behaviours, which can vary by geographical location. The prevalence estimates for methamphetamine were published over a longer-time frame and includes research from different continents (Europe, North America, Australia). This may be explained by the MSM population having a longer history of using this drug. Research examining mephedrone and GHB/GBL was primarily from Western Europe, with the exception of one recent study on GHB/GBL from Australia. It is not possible to evidence specific changes in drug trend’s, although type of drug use varies across different high-income regions/countries. As chemsex is a socially constructed phenomenon the use of specific drugs will vary across different cultures and MSM sub-populations. This limits the generalisability of findings which is reflected in the different studies consisting of greatly varied types of sample. The social constructed nature of chemsex accounts for the variation in prevalence estimates and types of drug used across the different geographical areas.

This review highlights that MSM who combine chemsex drugs with sex are engaging in high risk sexual behaviours, including CAI and esoteric acts. There is a lack of knowledge on the specific rates of CAI that occur during chemsex, but it is evident that behaviour is mediated by participants HIV status. There is substantive evidence in this review to demonstrate that some HIV negative MSM who participate in chemsex will engage in CAI. The Edmundson et al (2018) review concluded that engagement in sexualised drug use can lead to CAI. This correlates with the review’s findings which suggests that MSM who combine drugs with sex are more likely to engage in high risk sexual practices when compared to MSM who do not combine drugs with sex.

The studies from Western Europe and Australia which analysed the injection of drugs provided varied prevalence estimates for injecting drugs (1%-50%) for sexual purposes and for the sharing of injecting equipment (5%-56%). This may be accounted for by some studies using general samples and others recruiting smaller samples from high risk groups. A longitudinal analysis of MSM injecting drug use in Australia reported that between 5%-6% of the sample had injected in the previous 6 months (Lea et al, 2013). Edmundson et al (2018) identified that over a 15-year period the number of MSM attending UK drug services reporting injecting drug use had nearly doubled (4% to 8%) and there was a growth in the use of stimulants. However, it is important to highlight that the data within these publications did not exclusively focus on injecting for sexual purposes. The evidence shows that a small minority of the wider MSM population inject drugs but there is a lack of research examining MSM sexualised injecting of drugs.

This review indicates that high risk chemsex behaviours puts participants at increased risk of acquiring STIs/HIV and there is limited evidence that suggests there are psycho-social consequences. However, the majority of the evidence base regarding the risk of STIs and HIV is associative. There is also a lack of research which exclusively focused on the behaviour of HIV negative MSM and the associated consequences. The findings in this review supports work by Tomkins et al (2018) who reported that chemsex behaviour has a negative impact on some participants social
functioning and mental well-being. However, Prestage et al (2018) identified that drug use during sexual activity was not associated with depression. The study did identify that illicit drug use is associated with depression and anxiety when the use becomes problematic or dependent (Prestage et al, 2018). The earlier findings in the review indicates that between 14%-25% of chemsex participants have experienced a negative impact on their psycho-social functioning. The wider literature provides evidence which demonstrates that the higher the frequency of the drug use, the more detrimental the impact is on psycho-social well-being of the user, particularly if they engage in poly-drug use (Ives and Ghelani, 2009; European Monitoring Centre for Drugs and Drug Addiction, 2009). There is also the biological risk for poly-drug users who use different substances which can create highly toxic and dangerous reactions in the body. However, evidence for the impact of chemsex behaviours on psycho-social well-being is weak although it is anticipated that the potential consequences for frequent poly-drug users are significant.

The studies in the review that examined the use of STI/BBV screening, PEP and PrEP use did not provide substantive answers on how commonly chemsex participants use these interventions. The limited evidence indicates that a majority may either access screening or attend sexual health services but does not provide a clear understanding on frequency and type of testing. However, the recent publication from Frankis et al (2018) indicated that chemsex engagement is associated with men who had an HIV test in the previous three months. There is very limited evidence which suggests chemsex participants are more likely to access PEP and PrEP compared to MSM who do not engage in chemsex. However, it is possible that greater access to PrEP/PEP by chemsex participants is influenced by service providers. Sewell et al (2017) identified in a study of MSM chemsex drug users that the level of PEP use was 14% and PrEP use was 4.5%.

A clinical trial of PrEP reported that in the previous three months approximately 44% of the MSM sample had used methamphetamine, GHB/GBL or mephedrone (Dolling et al, 2016). In comparison, a recent study from Australia highlighted that the concurrent use of methamphetamine, EDDs and PrEP in 2014 was 1.9% but this increased to 6% in 2017 (Hammoud et al, 2018b). However, the paper by Hammoud et al (2018b) does not directly link the chemsex drug use episodes to PrEP use (Gafos et al, 2018). The overall evidence indicates that PrEP is being used by some MSM who use chemsex drugs, but the majority of previous research does not identify if the drug usage is within a sexual setting. As PrEP is a relatively new innovation it is important to understand how chemsex participants use the range of bio-medical interventions. This remains an important research question as the introduction of PrEP could potentially influence how chemsex participants use other interventions and chemsex behaviours may influence the participants PrEP adherence.

This review adopted a precise and clear systematic methodology to address it’s objectives. A strength is the explicit inclusion/exclusion criteria which focused on the use of chemsex drugs before or during sex. However, is not able to determine if the sexual activity was planned. The review is limited by the absence of clear sampling frames in the published studies and the resulting heterogeneity of predominantly purposive samples across the studies. The review may also be limited by its exclusion of research from low to medium income countries and by including only English language articles.
To enable improved future research into chemsex it may be beneficial to develop standardised questioning that identifies if chemsex drug use is before or during planned sexual activity. The review has identified some key research gaps and recommends future research in the following areas: i) research exclusively on HIV negative MSM chemsex behaviours; ii) explore and examine the prevalence and risk behaviours of MSM who inject chemsex drugs for sexual purposes; iii) examine MSM chemsex participants use of bio-medical interventions, specifically the use of PEP and PrEP; and iv) in-depth exploration on the psycho-social impact on MSM who engage in chemsex. These research recommendations reflect components in Fig. 2 and relationships between them. The ABC model was a useful conceptual framework in the synthesis of the evidence and it’s use would be worth considering to inform future work. Research in these areas could improve the efficiency and targeting of risk reduction interventions that reduce the biopsychosocial impact of chemsex behaviours.

**Conclusion**

It appears a minority of MSM engage in chemsex behaviour, but there are interconnected high-risk behaviours associated with the activity. The examination of chemsex is limited due to the challenge in defining the activity and there are limitations in comparing prevalence estimates due to the use of different sampling frameworks. However, there are potentially multiple consequences associated with chemsex behaviour although this remains an under researched area. With the increasing availability of PrEP, it is important to understand how bio-medical interventions can be effectively used to reduce the potential impact of high risk chemsex behaviours among this population.

**Acknowledgements**

The authors would like to thank Jane Sedgwick and Iain Ryrie of King’s College London for their support with the review.

**Funding**

This research did not receive any specific grants or awards.
Reference List


Liberati, A; Altman, G; Tetzlaff, J; Gotzsche, C; Ionidis, P; Moher, D. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Plos Medicine, 6.


